Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 10/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 5/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17229666 | 0.89 | OPRL1 (0.43) | OPRL1HSD11B1GRM5NPC1TRPV1 | |
| SCHEMBL17232805 | 0.82 | SLC9A1 (0.54) | KCNH2 | |
| SCHEMBL17234874 | 0.80 | SCD5 (0.56) | OPRL1HSD11B1GRM5 | |
| SCHEMBL19993076 | 0.79 | OPRL1 (0.53) | OPRL1KCNH2OPRM1 | |
| SCHEMBL17232806 | 0.78 | RBP4 (0.53) | KCNH2 | |
| SCHEMBL16951709 | 0.78 | OPRL1 (0.59) | OPRL1KCNH2OPRM1 | |
| SCHEMBL17229667 | 0.77 | DRD4 (0.42) | TRPV1 | |
| SCHEMBL17229668 | 0.77 | RBP4 (0.37) | OPRL1NPC1 | |
| SCHEMBL17229661 | 0.77 | OPRL1 (0.42) | OPRL1 | |
| SCHEMBL3436615 | 0.77 | OPRL1 (0.50) | OPRL1KCNH2OPRM1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649240-B2 | Substituted 4-phenylpiperidines, their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-05-16 | — | — | US | disclosed |
| US-20180030060-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-02-01 | — | — | US | disclosed |
| US-9777010-B2 | Substituted 4-phenylpiperidines, their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160368925-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-12-22 | — | — | US | disclosed |
| US-9434727-B2 | Substituted 4-phenylpiperidines, their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-09-06 | — | — | US | disclosed |
| US-20150315197-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315197-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | HRH4, HRH3, HRH2 | OPRL1 503/4885KCNH2 16/4885OPRM1 450/4885 |
| US-20160368925-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | HRH4, HRH3, HRH2 | OPRL1 488/4885KCNH2 17/4885OPRM1 445/4885 |
| US-20180030060-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | HRH4, HRH3, HRH2 | OPRL1 503/4885KCNH2 16/4885OPRM1 450/4885 |
| US-11649240-B2 | Substituted 4-phenylpiperidines, their preparation and use | HRH4, HRH3, HRH2 | OPRL1 503/4885KCNH2 16/4885OPRM1 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.